FRE.DE: Summary for FRESENIUS SE+CO.KGAA O.N. - Yahoo Finance

UK Markets close in 6 hrs 7 mins

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
72.85-0.08 (-0.11%)
As of 11:06AM CET. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close72.93
Bid72.85 x 120700
Ask72.86 x 6100
Day's range72.55 - 73.02
52-week range60.00 - 77.45
Avg. volume946,628
Market cap40.36B
PE ratio (TTM)25.12
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Fresenius SE & Co. KGaA breached its 50 day moving average in a Bearish Manner : FRE-DE : March 13, 2017
    Capital Cube10 days ago

    Fresenius SE & Co. KGaA breached its 50 day moving average in a Bearish Manner : FRE-DE : March 13, 2017

    Categories: Europe Stock Alerts Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Fresenius SE & Co. KGaA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 ... Read more (Read more...)

  • Zacks Small Cap Research15 days ago

    CTSO: Several Catalysts Will Extend Record Revenue Streak Into 2017

    CytoSorbents (CTSO) reported financial results for the fourth quarter ending December 31st and provided a business update.  Total revenue and product sales continue to show considerable strength, rising for the seventh straight quarter and catalyzed by CytoSorb cartridge (“razor blade”) reorders as well as new customer wins and expansion of the distribution footprint. Both product sales and total revenue set new records in Q4.  Q4 product sales were up 74% yoy and 22% sequentially to $2.6M.  Meanwhile, total revenue (which along with product sales includes grant revenue) grew 75% yoy and 28% sequentially to $3.1M.  As we have stressed in the past, we are encouraged by the high quality product revenue growth – that is, mostly reorders, no channel stuffing or lumpy distributor stocking – which we believe offers a certain level of validation of burgeoning demand and by extension, clinical utility of CytoSorb.

  • Associated Press28 days ago

    Fresenius Medical Care misses 4Q revenue forecasts

    Fresenius Medical Care AG (FMS) on Wednesday reported fourth-quarter net income of $388 million. The Bad Homburg, Germany-based company said it had net income of 63 cents per American depositary share. ...